KRAS伴隨診斷市場：策略洞察與預測（2026-2035年）

KRAS伴隨診斷市場預計將從2026年的14.3億美元成長到2035年的43.3億美元，複合年成長率為13.1%。

在精準腫瘤學模式轉移和KRAS標靶治療近期快速發展的推動下，KRAS伴隨診斷市場正經歷著顯著的變革。這一市場演變的特徵是，人們日益認知到，準確識別特定的KRAS突變對於制定治療策略至關重要，因為治療合格越來越依賴精確的分子特徵分析。聚合酵素鏈鎖反應（PCR）、次世代定序和液態生物檢體等先進分子技術的融合，使得KRAS突變的檢測速度更快、更全面、更便捷。隨著臨床證據日益支持個人化治療策略，醫療系統正將分子檢測納入治療過程的早期階段。藥物創新不斷拓展KRAS標靶治療方案，使得人們越來越依賴能夠識別臨床適用突變的、檢驗的伴隨診斷平台。隨著標靶治療越來越依賴檢驗生物標記的識別，監管機構正在收緊對伴隨診斷的要求。隨著市場對綜合基因組分析、液態生物檢體技術和人工智慧驅動的解讀工具的大量投資，KRAS伴隨診斷正在成為全球醫療保健系統中精準腫瘤學的關鍵組成部分。

市場促進因素

• KRAS標靶療法的擴展是KRAS伴隨診斷市場的主要驅動力。 KRAS伴隨診斷仍然至關重要，因為標靶治療需要在治療開始前確認特定突變。隨著精準腫瘤學在臨床實踐中日益普及，製藥公司正在擴大其以KRAS為重點的治療計畫。隨著治療專業化程度的提高，所有腫瘤治療領域對精準突變檢測的需求都在成長。診斷設備製造商正在加強其檢測平台，以跟上不斷發展的治療路徑。這一趨勢正在增強對檢驗的伴隨診斷的長期需求，從而推動KRAS伴隨診斷的持續成長。精準腫瘤學的日益普及透過對分子特徵分析的需求進一步加速了市場成長。精準腫瘤學依賴分子特徵分析，因為治療結果越來越依賴基因組圖譜。醫療服務提供者正在患者管理的早期階段納入全面的生物標記檢測。傳統的治療方法往往缺乏足夠的個人化指南，因此需要更精確的分子評估。診斷公司正在擴展其基因組檢測能力，以滿足這些不斷變化的需求。這種轉變正在推動KRAS伴隨診斷的需求。全面基因組分析的日益普及正在加速更廣泛的分子評估的應用。全面基因組分析透過同時評估可用於多種療法的生物標記物，從而改善臨床決策。隨著臨床醫生尋求更深入了解腫瘤的生物學特徵，需求正轉向更廣泛的分子表徵。序貫檢測方法通常會導致更長的檢測時間和更高的資源消耗。診斷實驗室正在採用NGS技術來提高效率和覆蓋範圍。這一趨勢正在推動先進伴隨診斷解決方案的應用。隨著抗藥性監測變得越來越重要，KRAS伴隨診斷的臨床效用正在疾病的整個進展過程中不斷擴展。隨著疾病的進展，腫瘤通常會獲得更多的分子突變，而治療抗藥性會影響治療結果。臨床醫生越來越依賴基因組變化監測來最佳化後續的治療策略。

市場限制因素

• 先進分子檢測的高成本可能會限制醫療系統在報銷機制受限的情況下採用這些技術。先進技術所需的大量資金投入對小規模的醫療機構和發展中地區構成障礙。分子診斷基礎設施的差異可能會限制某些地區獲得標準化KRAS檢測服務。專業實驗室和訓練有素的人員短缺限制了分子診斷的擴充性。監管和檢驗要求增加了研發的複雜性，並延長了伴隨診斷試劑生產商的產品上市時間。嚴格的證據要求給研發人員帶來了巨大的時間和成本負擔。不同司法管轄區法規的複雜性也給尋求將新型診斷解決方案商業化的製造商帶來了合規方面的負擔。

技術與癌症適應症的見解

• 技術發展趨勢的特徵是全面基因組分析和整合分子檢測平台的重要性日益凸顯。 PCR 仍然被廣泛應用，因為許多具有臨床意義的 KRAS 突變需要在治療開始前進行快速靶向檢測。然而，隨著更廣泛的基因組分析能夠提供超越單一 KRAS 突變的更深入信息，市場需求正轉向 NGS。當多個適用的生物標記共存於同一腫瘤時，單基因檢測方法往往限制了我們對分子層面疾病的理解。臨床檢查室正在擴大 NGS 的應用範圍，以提高檢測效率並支持全面的精準腫瘤學計畫。 Sanger定序在確診和探索性應用中仍然發揮著至關重要的作用。液態生物檢體透過非侵入性突變檢測擴大了檢測的可及性。片段分析表明，非小細胞肺癌 (NSCLC) 是一個關鍵的應用領域，因為 KRAS 突變直接影響治療選擇和預後。大腸直腸癌也是 KRAS 突變檢測指導抗 EGFR 治療決策的主要應用領域之一。隨著KRAS標靶療法的擴展，胰臟癌和其他固體癌的發生率正在迅速成長。組織切片檢查仍然是檢測KRAS突變的關鍵臨床標準。當組織檢體有限時，液態生物檢體作為一種微創診斷方法正日益普及，有助於對疾病進行時間序列監測。臨床診斷檢查室是主要的終端使用者群體，醫院和專科癌症中心正在不斷擴展其檢測能力。隨著基因組複雜性的增加，分析挑戰也日益嚴峻，人工智慧的整合變得越發重要。技術開發人員正在將人工智慧整合到分子診斷中，以增強決策支援能力。

競爭格局與策略展望

• 在競爭激烈的市場格局中，除了成熟的診斷和生命科學公司外，專注於精準腫瘤學和液態生物檢體的供應商也加入了競爭行列。羅氏憑藉其全球腫瘤治療產品組合以及在精準醫療領域最成熟的伴隨診斷業務之一，繼續保持戰略領先地位。該公司透過其cobas平台和與藥物研發活動緊密結合的精準腫瘤學舉措，持續推動分子診斷技術的進步。凱傑憑藉其在分子診斷、生物標記檢測和伴隨診斷開發方面的豐富經驗脫穎而出，並持續開發分子檢測方法和戰略合作夥伴關係，以支持精準醫療的應用。賽默飛世爾科技憑藉其廣泛的生命科學和診斷產品組合，為基因組檢測、定序技術和分子分析提供支持，並持續投資於定序技術和以腫瘤學為重點的診斷解決方案，保持著重要的戰略地位。安捷倫憑藉其病理學和分子診斷參與企業，為整體腫瘤學領域的生物標記評估提供支持，並持續提升其診斷能力，從而提高工作流程效率和臨床可靠性，仍然是市場的重要參與者。隨著新一代定序技術（NGS）在腫瘤學領域日益支持全面的分子表徵，Illumina 的策略地位仍舉足輕重，該公司持續開發定序平台，以支持伴隨診斷應用和精準腫瘤學。 Bio-Rad 透過支持突變檢測和分析準確性的分子診斷技術為市場做出貢獻。 Guardant Health 則憑藉其在液態生物檢體技術領域的領先地位脫穎而出，這些技術支持非侵入性基因組分析和疾病監測。隨著全面的基因組分析日益支持個人化癌症治療決策，Foundation Medicine 的策略地位依然舉足輕重。各公司都在致力於透過 NGS 晶片、液態生物檢體檢測和人工智慧驅動的解讀工具的創新來拓展產品系列。在標靶治療的同時開發伴隨診斷的需求不斷成長的推動下，診斷設備製造商和製藥公司之間的策略合作日益增加。地理擴張仍然是關鍵的策略重點，各公司都將目光投向了快速成長的亞太地區和醫療基礎設施不斷完善的新興市場。

簡明結論

• 受標靶治療的擴展、全面的基因組分析以及技術創新融合的推動，KRAS伴隨診斷市場預計將持續成長。從單基因檢測到全面基因組分析的轉變，標誌著精準腫瘤學領域的根本性變革。儘管高成本、基礎設施限制和監管複雜性等挑戰依然存在，但對技術、夥伴關係和實證醫學的策略性投資正為市場領導帶來持續的競爭優勢。長期市場前景依然樂觀，KRAS伴隨診斷將發展成為精準腫瘤學的關鍵組成部分，支持全球醫療系統進行精準的患者分層、最佳化治療方案並改善臨床療效。

本報告的主要特點

• 深入分析：對各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業部門進行詳細的市場洞察。
• 競爭格局：了解主要參與者的策略舉措，並確定最佳的市場進入方式。
• 市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
• 實用建議：我們支援制定策略決策以開發新的收入來源。
• 適合各類讀者：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

公司對我們報告的使用

• 產業和市場洞察、機會評估、產品需求預測、打入市場策略、區域擴張、資本投資決策、監管分析、新產品開發和競爭情報。

調查範圍

• 歷史資料涵蓋 2021 年至 2024 年，基準年為 2025 年，預測期為 2026 年至 2035 年。
• 成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
• 競爭對手定位、策略、市場佔有率評估和貿易分析
• 細分市場和區域銷售成長及預測評估
• 公司簡介，包括策略、產品、財務狀況和主要發展動態。

目錄

第1章執行摘要

• 市場概述
• 主要發現
• 分析師意見
• 策略建議

第2章：調查方法

• 調查設計
• 資料收集和調查方法
• 市場規模估算
• 預測模型
• 先決條件和限制

第3章：EGFR伴隨診斷市場概況、規模及預測

• 市場定義和範圍
• EGFR標靶腫瘤學概述
• 產業變化
• 主要市場趨勢
• 市場規模表現分析
• 市場預測分析
• 疾病負擔與未滿足的臨床需求分析
• EGFR突變癌症的流行病學和盛行率分析
• 已確診患者族群的分析
• 對 EGFR 檢測數量的分析
• 精準腫瘤學採納現況分析
• 目前治療狀況及伴隨診斷的整合

第4章 市場動態

• 市場促進因素
• 市場限制因素
• 市場機遇
• 市場挑戰

第5章 行業情勢

• 產業價值鏈分析
• 定價分析
• 還款狀態

第6章：創新趨勢

• EGFR檢測領域的新興技術
• 產品創新趨勢
• 臨床試驗分析
• EGFR伴隨診斷的流程分析
• 整合次世代定序
• 液態生物檢體和ctDNA檢測技術的創新
• 將人工智慧整合到基因組分析中
• 技術藍圖

第7章 監理情勢

• 法律規範
• 核准流程
• 合規要求

第8章：EGFR伴隨診斷市場分析

• 分析：按技術平台
• 分析：依生物標記類型
• 分析：依樣本類型
• 分析：透過臨床應用
• 分析方法：透過檢查和調查方法
• 分析：按癌症適應症

第9章 EGFR伴隨診斷市場的市場區隔

• 透過技術
  • 聚合酵素鏈鎖反應（PCR）
  • 次世代定序（NGS）
  • 桑格定序
  • 螢光原位雜合反應（FISH）
  • 免疫組織化學（IHC）
  • 其他技術
• 癌症適應症類型
  • 非小細胞肺癌（NSCLC）
  • 結腸癌
  • 膠質母細胞瘤
  • 頭頸癌
  • 其他固體癌
• 按突變類型
  • 埃克森-19號失踪
  • L858R突變
  • T790M突變
  • 埃克森-20插入
  • 其他EGFR突變
• 依樣本類型
  • 組織切片檢查
  • 液態生物檢體
• 最終用戶
  • 醫院
  • 臨床實驗室
  • 學術研究機構
  • 專科癌症中心

第10章：EGFR伴隨診斷市場區域分析

• 北美洲
• 歐洲
• 亞太地區
• 南美洲
• 中東和非洲

第11章：EGFR伴隨診斷市場國別分析

• 美國
• 加拿大
• 德國
• 英國
• 法國
• 義大利
• 西班牙
• 日本
• 中國
• 韓國
• 澳洲
• 印度
• 巴西
• 沙烏地阿拉伯

第12章 競爭格局

• 市佔率分析
• 策略趨勢
• 併購、合作與聯盟
• 新產品發布

第13章：公司簡介

• F. Hoffmann-La Roche Ltd.
• QIAGEN NV
• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Illumina, Inc.
• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Guardant Health, Inc.
• Foundation Medicine, Inc.
• NeoGenomics Laboratories, Inc.
• Sysmex Corporation
• Myriad Genetics, Inc.
• Leica Biosystems Nussloch GmbH
• PERSONALIS, INC.

第14章：EGFR伴隨診斷市場商業性預測分析

第15章：投資與資金籌措分析

• 創業投資趨勢
• 政府資金
• 研發投資

第16章：未來展望

• 主要成長機遇
• 未來產業趨勢

The KRAS Companion Diagnostics Market is anticipated to grow at a CAGR of 13.1% from USD 1.43 billion in 2026 to USD 4.33 billion in 2035.

The KRAS companion diagnostics market is undergoing significant transformation driven by the paradigm shift toward precision oncology and the recent expansion of KRAS-targeted therapies. The market's evolution is characterized by the growing recognition that accurate identification of specific KRAS mutations is essential for therapeutic decision-making, as treatment eligibility increasingly depends on precise molecular characterization. The convergence of advanced molecular technologies, including polymerase chain reaction, next-generation sequencing, and liquid biopsy, is enabling faster, more comprehensive, and increasingly accessible KRAS mutation detection. Healthcare systems are incorporating molecular testing earlier in treatment pathways as clinical evidence increasingly supports personalized treatment strategies. Pharmaceutical innovation continues expanding KRAS-directed therapeutic options, creating greater dependence on validated companion diagnostic platforms capable of identifying clinically actionable mutations. Regulatory agencies are strengthening companion diagnostic requirements because targeted therapies increasingly depend on validated biomarker identification. The market is witnessing significant investment in comprehensive genomic profiling, liquid biopsy technologies, and AI-enabled interpretation tools, positioning KRAS companion diagnostics as a critical component of precision oncology across global healthcare systems.

Market Drivers

• The expansion of KRAS-targeted therapeutics represents the primary driver for the KRAS companion diagnostics market. KRAS companion diagnostics remain essential because targeted therapies require confirmation of specific mutations before treatment initiation. Pharmaceutical companies are expanding KRAS-focused therapeutic programs as precision oncology becomes more integrated into clinical practice. Growing therapeutic specialization increases demand for accurate mutation detection across oncology care settings. Diagnostic manufacturers are enhancing testing platforms to support evolving treatment pathways. This trend strengthens long-term demand for validated companion diagnostics, resulting in sustained growth in KRAS companion diagnostic utilization. The increasing adoption of precision oncology is further accelerating market growth through demand for molecular characterization. Precision oncology depends on molecular characterization because treatment outcomes increasingly vary according to genomic profiles. Healthcare providers are incorporating comprehensive biomarker testing earlier in patient management. Conventional treatment approaches often provide less individualized therapeutic guidance, creating pressure for more precise molecular assessment. Diagnostic companies are expanding genomic testing capabilities to support these evolving requirements. This transition reinforces demand for KRAS companion diagnostics. The growing utilization of comprehensive genomic profiling is driving adoption of broader molecular assessment. Comprehensive genomic profiling improves clinical decision-making because multiple actionable biomarkers can be evaluated simultaneously. Demand is shifting toward broader molecular characterization as clinicians seek deeper insights into tumor biology. Sequential testing approaches often increase turnaround times and resource utilization. Diagnostic laboratories are implementing NGS technologies to improve efficiency and testing scope. This development strengthens adoption of advanced companion diagnostic solutions. The increasing importance of resistance monitoring is expanding the clinical utility of KRAS companion diagnostics throughout disease progression. Treatment resistance influences therapeutic outcomes because tumors frequently acquire additional molecular alterations during disease progression. Clinicians are increasingly monitoring genomic changes to optimize subsequent treatment strategies.

Market Restraints

• High costs associated with advanced molecular testing can limit adoption in healthcare systems with constrained reimbursement structures. The significant financial investment required for advanced technologies creates barriers for smaller facilities and developing regions. Variability in molecular diagnostic infrastructure can restrict access to standardized KRAS testing services across certain regions. The shortage of specialized laboratories and trained personnel limits the scalability of molecular diagnostics. Regulatory and validation requirements increase development complexity and commercialization timelines for companion diagnostic manufacturers. The rigorous evidence requirements create significant time and cost burdens for developers. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Cancer Indication Insights

• The technology landscape is characterized by the growing importance of comprehensive genomic profiling and integrated molecular testing platforms. PCR remains widely adopted because many clinically actionable KRAS mutations require rapid and targeted detection before treatment initiation. Demand is shifting toward NGS because broader genomic profiling provides additional insights beyond individual KRAS alterations. Single-gene testing approaches often limit molecular understanding when multiple actionable biomarkers coexist within the same tumor. Clinical laboratories are expanding NGS implementation to improve testing efficiency and support comprehensive precision oncology programs. Sanger sequencing remains important for confirmation and research applications. Liquid biopsy is expanding testing accessibility through non-invasive mutation detection. The segment analysis reveals that NSCLC represents a significant application because KRAS mutations directly influence treatment selection and therapeutic outcomes. Colorectal cancer represents another major application where KRAS mutation testing guides anti-EGFR therapy decisions. Pancreatic cancer and other solid tumors represent growing segments as KRAS-targeted therapies expand. Tissue biopsy remains the clinical reference standard for KRAS mutation detection. Liquid biopsy is expanding for minimally invasive testing when tissue samples are limited, supporting longitudinal disease monitoring. Clinical diagnostic laboratories represent the leading end-user segment, with hospitals and specialty cancer centers expanding testing capabilities. The integration of AI is becoming increasingly important because genomic complexity increases analytical challenges. Technology developers are integrating AI into molecular diagnostics to enhance decision support capabilities.

Competitive and Strategic Outlook

• The competitive landscape features established diagnostics and life science companies alongside specialized precision oncology and liquid biopsy providers. Roche remains strategically distinct because it combines a global oncology therapeutics portfolio with one of the most established companion diagnostics businesses in precision medicine, continuing to advance molecular diagnostics through its cobas platform and precision oncology initiatives that align closely with pharmaceutical development activities. QIAGEN differentiates itself through extensive expertise in molecular diagnostics, biomarker testing, and companion diagnostic development, continuing to develop molecular assays and strategic collaborations that support precision medicine applications. Thermo Fisher Scientific maintains strategic relevance because its broad life sciences and diagnostics portfolio supports genomic testing, sequencing technologies, and molecular analysis, continuing to invest in sequencing technologies and oncology-focused diagnostic solutions. Agilent remains an important market participant because its pathology and molecular diagnostic technologies support biomarker assessment across oncology applications, continuing to enhance diagnostic capabilities that improve workflow efficiency and support clinical confidence. Illumina remains strategically important because NGS increasingly supports comprehensive molecular characterization within oncology, continuing to advance sequencing platforms that support companion diagnostic applications and precision oncology initiatives. Bio-Rad contributes to the market through molecular diagnostic technologies that support mutation detection and analytical precision. Guardant Health differentiates itself through leadership in liquid biopsy technologies that support non-invasive genomic profiling and disease monitoring. Foundation Medicine remains strategically important because comprehensive genomic profiling increasingly supports personalized oncology treatment decisions. Companies are pursuing product portfolio expansion through innovation in NGS panels, liquid biopsy assays, and AI-enabled interpretation tools. Strategic collaborations between diagnostic manufacturers and pharmaceutical companies are increasing, driven by the need for companion diagnostic development alongside targeted therapies. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

• The KRAS companion diagnostics market is positioned for sustained growth driven by the convergence of targeted therapy expansion, comprehensive genomic profiling, and technological innovation. The transition from single-gene testing toward comprehensive genomic profiling represents a fundamental shift in precision oncology. While challenges related to high costs, infrastructure limitations, and regulatory complexity persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with KRAS companion diagnostics evolving into a critical component of precision oncology, supporting accurate patient stratification, treatment optimization, and improved clinical outcomes across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. EGFR Companion Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 EGFR-Driven Oncology Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast Analysis (2026-2035)
• 3.7 Disease Burden and Unmet Clinical Needs Analysis
• 3.8 Epidemiology and Prevalence Analysis of EGFR-Mutated Cancers
• 3.9 Diagnosed Patient Population Analysis
• 3.10 EGFR Testing Volume Analysis
• 3.11 Precision Oncology Adoption Analysis
• 3.12 Treatment Landscape and Companion Diagnostic Integration

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies in EGFR Testing
• 6.2 Product Innovation Trends
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis of EGFR Companion Diagnostics
• 6.5 Next-Generation Sequencing Integration
• 6.6 Liquid Biopsy Innovation and ctDNA Testing
• 6.7 AI Integration in Genomic Interpretation
• 6.8 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. EGFR Companion Diagnostics Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Biomarker Type
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Clinical Application
• 8.5 Analysis by Testing Methodology
• 8.6 Analysis by Cancer Indication

9. EGFR Companion Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Technology
  • 9.1.1 Polymerase Chain Reaction (PCR)
  • 9.1.2 Next-Generation Sequencing (NGS)
  • 9.1.3 Sanger Sequencing
  • 9.1.4 Fluorescence In Situ Hybridization (FISH)
  • 9.1.5 Immunohistochemistry (IHC)
  • 9.1.6 Other Technologies
• 9.2 By Cancer Indication
  • 9.2.1 Non-Small Cell Lung Cancer (NSCLC)
  • 9.2.2 Colorectal Cancer
  • 9.2.3 Glioblastoma
  • 9.2.4 Head and Neck Cancers
  • 9.2.5 Other Solid Tumors
• 9.3 By Mutation Type
  • 9.3.1 Exon 19 Deletion
  • 9.3.2 L858R Mutation
  • 9.3.3 T790M Mutation
  • 9.3.4 Exon 20 Insertions
  • 9.3.5 Other EGFR Mutations
• 9.4 By Sample Type
  • 9.4.1 Tissue Biopsy
  • 9.4.2 Liquid Biopsy
• 9.5 By End User
  • 9.5.1 Hospitals
  • 9.5.2 Clinical Diagnostic Laboratories
  • 9.5.3 Academic and Research Institutes
  • 9.5.4 Specialty Cancer Centers

10. EGFR Companion Diagnostics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. EGFR Companion Diagnostics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 South Korea
• 11.11 Australia
• 11.12 India
• 11.13 Brazil
• 11.14 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
• 13.2 QIAGEN N.V.
• 13.3 Thermo Fisher Scientific Inc.
• 13.4 Agilent Technologies, Inc.
• 13.5 Illumina, Inc.
• 13.6 Abbott Laboratories
• 13.7 Bio-Rad Laboratories, Inc.
• 13.8 Danaher Corporation
• 13.9 Guardant Health, Inc.
• 13.10 Foundation Medicine, Inc.
• 13.11 NeoGenomics Laboratories, Inc.
• 13.12 Sysmex Corporation
• 13.13 Myriad Genetics, Inc.
• 13.14 Leica Biosystems Nussloch GmbH
• 13.15 PERSONALIS, INC.

14. EGFR Companion Diagnostics Market Commercial Forecast Analysis

• 14.1 PCR-Based EGFR Companion Diagnostics
• 14.2 NGS-Based EGFR Companion Diagnostics
• 14.3 Tissue Biopsy-Based EGFR Testing Solutions
• 14.4 Liquid Biopsy-Based EGFR Testing Solutions
• 14.5 NSCLC Companion Diagnostics
• 14.6 T790M Mutation Detection Solutions
• 14.7 Comprehensive Genomic Profiling Platforms

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends